Sana Biotechnology, Inc.
NASDAQ:SANABiotechnology
+$0.04 today
- Market cap
- $554.32M
- Beta
- 2.16
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.87
Volume 2.66M
Average 3.76M
SANA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Sana Biotechnology, Inc.NASDAQ: SANA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $2.39M fell 34.5% year over year, behind the -33.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 21.7% from the prior quarter. Over 3 fiscal years it compounded at -6.6% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -34.5% toward the trailing-twelve-month pace of -33.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 12.75M USD
- Year-over-year change
- -26.7%
- 4-year CAGR
- +3.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.75M | -26.7% |
| FY2024 | 2024-12-31 | 17.39M | -29.2% |
| FY2023 | 2023-12-31 | 24.56M | +57.2% |
| FY2022 | 2022-12-31 | 15.63M | +41.1% |
| FY2021 | 2021-12-31 | 11.07M | — |
Depreciation & Amortization vs competitors
How SANA compares with its peers on the latest reported figures
- SANA's LTM Mar 2026 depreciation & amortization of $11.5M is the 7th largest of the 11 companies compared; the peer median is $11.92M.
- Its year-over-year change of -33.5% is the 10th highest of 11, against a peer median of -2.9%.
- Over three fiscal years its annual growth of -6.6% compares with a peer median of +3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $50.27M | +111.9% | +16.3% | 3.7% | |
| LTM Jun 2026 | $22.24M | +1.2% | +16.4% | 14.3% | |
| LTM Sep 2026 | $18.5M | -0.9% | -6.9% | 73.5% | |
| LTM Mar 2026 | $12.88M | -3.1% | +15.8% | — | |
| LTM Mar 2026 | $12.13M | -8.0% | -4.7% | — | |
| LTM Mar 2026 | $11.71M | -33.0% | -12.3% | 185.5% | |
| LTM Mar 2026 | $11.5M | -33.5% | -6.6% | — | |
| LTM Mar 2026 | $9.99M | -2.7% | +10.7% | 15.1% | |
| LTM Mar 2026 | $2.69M | -30.3% | -32.6% | 6.0% | |
| LTM Mar 2026 | $314K | +2.6% | +49.5% | — | |
| LTM Mar 2026 | $175K | -96.8% | -25.1% | 0.8% | |
| Peer median (excluding SANA) | $11.92M | -2.9% | +3.0% | 14.3% | |
Competitors are the stored peer set for SANA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Depreciation & Amortization | 11.07M | 15.63M | 24.56M | 17.39M | 12.75M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.36M | 38.34M | 35.53M | 37.68M | 25.46M |
| Change in Working Capital | 9.8M | 7.54M | 18.61M | (1.19M) | (10.11M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (266K) | 1.06M | 1.03M | 1.38M | (3.55M) |
| Other Working Capital | 10.07M | 6.48M | 17.58M | (2.56M) | (6.57M) |
| Other Non-Cash Items | 61.64M | (82.08M) | (49.03M) | (10.28M) | 72.24M |
| Operating Cash Flow | (251.05M) | (290.05M) | (253.58M) | (223.15M) | (143.83M) |
| Capital Expenditures | (29.86M) | (20.88M) | (20.03M) | (33.43M) | (938K) |
| Acquisitions (Net) | 0 | (231.44K) | (192.04K) | 0 | 1.43M |
| Purchases of Investments | (491.39M) | (78.69M) | (157.74M) | (226.06M) | (87.29M) |
| Sales of Investments | 280.03M | 310.13M | 349.79M | 276.95M | 46.56M |
| Other Investing Activities | (4.57M) | 231.44K | 192.04K | 17.45M | 0 |
| Investing Cash Flow | (245.8M) | 210.56M | 172.01M | 17.45M | (40.24M) |
| Debt Repayment | 0 | 0 | 0 | 7.74M | (347K) |
| Common Stock Issued | 631.75M | 4.91M | 31.65M | 181M | 129.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 11.01M | 0 |
| Financing Cash Flow | 631.75M | 4.91M | 31.65M | 199.75M | 128.73M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 134.9M | (74.58M) | (49.92M) | (5.95M) | (55.33M) |
| Free Cash Flow | (280.92M) | (310.93M) | (273.61M) | (256.58M) | (144.77M) |
Sana Biotechnology, Inc.
NASDAQ:SANA
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.